Compare NNBR & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NNBR | VNDA |
|---|---|---|
| Founded | 1980 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.8M | 301.1M |
| IPO Year | 1996 | 2005 |
| Metric | NNBR | VNDA |
|---|---|---|
| Price | $3.95 | $4.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.67 | ★ $11.75 |
| AVG Volume (30 Days) | ★ 2.2M | 778.6K |
| Earning Date | 10-28-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.60 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $770,657,000.00 | $216,105,000.00 |
| Revenue This Year | $13.55 | $15.16 |
| Revenue Next Year | $8.08 | $35.50 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $1.10 | $4.27 |
| 52 Week High | $4.59 | $9.91 |
| Indicator | NNBR | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 33.10 |
| Support Level | $3.40 | $4.45 |
| Resistance Level | $4.45 | $5.37 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 46.24 | 20.92 |
NN Inc is a diversified industrial company that combines engineering and production capabilities with materials science expertise to design and manufacture high-precision components and solutions. The company operates through two segments: Mobile Solutions, which generates maximum revenue and focuses on the automotive, general industrial, and medical end markets, manufacturing tight-tolerance components used in battery electric, hybrid electric, and internal combustion engine vehicles, braking, transmissions, fuel systems, HVAC, and diesel systems; and Power Solutions, which focuses on the electrical, general industrial, automotive, medical, and aerospace and defense end markets and manufactures high-precision metal components, assemblies, contact assemblies, and precision stampings.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.